Anormal Uterin Kanamaların Medikal Tedavisinde Progesteron Türevlerinin Yeri
Özet
Anormal uterin kanama (AUK), kadınlarda sık görülen ve yaşam kalitesini düşüren jinekolojik bir patolojidir. Tedavisinde, endometrium üzerindeki östrojenik etkiyi dengeleyen progesteron türevleri medikal seçenek olarak yaygın şekilde kullanılır. Bu türevlerden medroksiprogesteron asetat, yüksek biyoyararlanıma sahip olmakla birlikte uzun vadede meme kanseri ve koroner kalp hastalığı riskini artırabilir. Bir retroprogesteron olan didrogesteron, düşük dozlarda bile etkilidir ve rutin dozlarda ovulasyonu inhibe etmez. Mikronize doğal progesteron, biyolojik olarak over kaynaklı hormona özdeş olup kardiyovasküler sistem üzerinde nötr etkiye sahiptir. Güçlü androjenik etki gösteren noretisteron, AUK tedavisinde yüksek etkinlik sunar ancak tromboemboli gibi riskleri artırır. Rahim içi sistem olarak uygulanan levonorgestrel ise lokal etkisiyle pre-sistemik eliminasyonu önler, hem hemoglobin seviyelerini hem de yaşam kalitesini standart oral tedavilerden daha etkili bir şekilde artırır. Her bir progesteron türevinin seçimi; hastanın yaşına, etki mekanizmasına, yan etki profiline ve vajinal kanama, malignite veya karaciğer bozukluğu gibi kontrendikasyon durumlarına göre belirlenir.
Abnormal uterine bleeding (AUB) is a common gynecological pathology in women that reduces the quality of life. Progesterone derivatives, which balance the estrogenic effect on the endometrium, are widely used as a medical option in its treatment. Among these derivatives, medroxyprogesterone acetate has high bioavailability but may increase the risk of breast cancer and coronary heart disease in the long term. Dydrogesterone, a retroprogesterone, is effective even at low doses and does not inhibit ovulation at routine doses. Micronized natural progesterone is biologically identical to the ovarian hormone and has a neutral effect on the cardiovascular system. Norethisterone, which exhibits a strong androgenic effect, offers high efficacy in AUB treatment but increases risks such as thromboembolism. Levonorgestrel, applied as an intrauterine system, prevents pre-systemic elimination through its local effect and improves both hemoglobin levels and quality of life more effectively than standard oral treatments. The selection of each progesterone derivative is determined based on the patient's age, mechanism of action, side effect profile, and contraindications such as undiagnosed vaginal bleeding, malignancy, or liver dysfunction.
Referanslar
Munro MG, Critchley HOD, Fraser IS, Committee FMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393-408.
Munro MG, Critchley HO, Broder MS, Fraser IS, Disorders FWGoM. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13.
Goldstein SR, Lumsden MA. Abnormal uterine bleeding in perimenopause. Climacteric. 2017;20(5):414-20.
Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016;214(1):31-44.
Jewson M, Purohit P, Lumsden MA. Progesterone and abnormal uterine bleeding/menstrual disorders. Best Practice & Research Clinical Obstetrics & Gynaecology. 2020;69:62-73.
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2003;46 Suppl 1:S7-S16.
Kuhl H. Pharmacology of progestins. Basic aspects-progesterone derivatives. Menopause Rev. 2001;6:9-16.
Gompel A. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. Climacteric. 2018;21(4):321-5.
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Jama. 1998;280(7):605-13.
Bender RA. Medroxyprogesterone Acetate for Abnormal Uterine Bleeding Due to Ovulatory Dysfunction: The Effect of 2 Different-Duration Regimens. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2022;28:e936727-1.
Katzung B, Trevor A. Basic & clinical pharmacology, thirteenth. New York: McGraw Hill Education; 2015.
Brunton L, Hilal-Dandan R, Goodman LS. Goodman and Gilman manual of pharmacology and therapeutics: Mcgraw Hill Professional; 2013.
Ritter J, Flower R, Henderson G, Loke Y, MacEwan D, Rang H. Antidepressant drugs. Rang & Dale’s pharmacology 9th ed Edinburgh: Elsevier. 2020:603-22.
Mishell DR. Progestins and antiprogestins in clinical practice: Marcel Dekker; 1999.
de Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995;21(3):251-7.
Miller VT, LaRosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A, et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. Jama. 1995;273(3):199-208.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long‐term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. 2017(1).
Mueck A. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric. 2012;15(sup1):11-7.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast cancer research and treatment. 2008;107(1):103-11.
Golbs S, Nikolov R, Zimmermann T. Pharmacology of nortestosterone derivatives. Menopause Rev. 2001;6(1):29-44.
Portman DJ, Symons JP, Wilborn W, Kempfert NJ. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone. Am J Obstet Gynecol. 2003;188(2):334-42.
Randel A. Guidelines for the use of long-acting reversible contraceptives. American Family Physician. 2012;85(4):403-4.
Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J, et al. Levonorgestrel Intrauterine System Versus Medical Therapy for Menorrhagia. Obstetrical & Gynecological Survey. 2013;68(5):351-3.
Somboonporn W, Panna S, Temtanakitpaisan T, Kaewrudee S, Soontrapa S. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause. 2011;18(10):1060-6.
Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020;9:CD012658.
Collaborative Group on Hormonal Factors in Breast C. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-68.
